10 November 2021 | News
C2 PHARMA, a pharmaceutical group established focused on niche active pharmaceutical ingredients (APIs), has expanded the API product portfolio.
Multiple regulatory filings have been submitted to expand distribution channels globally across China, Taiwan, South Korea, Brazil, and Mexico. In addition, the company has successfully launched a Cyclopentolate Hydrochloride API in both the US and European markets to position the team as a leading ophthalmic API supplier.
“Since announcing our intentions to go through a growth spurt back in 2019 at the last live edition of CPhI Worldwide pre-COVID, we have been actively working to deliver on our promises. Our team is driven to offer the most reliable, quality focused products and support to our customers”, said Andrew Badrot, CEO of C2 PHARMA. “Since inception in 2014, C2 PHARMA has rapidly grown an API portfolio with over ten US-DMF and CEP filed in addition to all the local filings we are announcing today. COVID-19 has strengthened our commitment to operational excellence, and we are thrilled to be able to make so many strategic portfolio additions.”